Multiple Sclerosis Approval: Medical Marijuana, Inc. Subsidiary HempMeds® Brasil Receives Brazilian Government Permission for Import of Flagship Product RSHO™

SAN DIEGO, Feb. 21, 2017 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, subsidiary, HempMeds^® Brasil today announced that the Brazilian government has authorized a doctor's prescription for the Company's hemp cannabidiol (CBD) oil product Real Scientific Hemp Oil™ (RSHO™) to treat patients in the country suffering from Multiple Sclerosis.  

This marks the first time that Brazil's National Health Surveillance Agency ANVISA has granted the filling of a prescription for RSHO™ to specifically help patients combat the effects of Multiple Sclerosis. Per the Multiple Sclerosis International Federation (MSIF), more than 2.5 million people worldwide are affected by MS, a progressive disease of the central nervous system, for which there is currently no cure. In Brazil, MS prevalence is estimated to range from 1.36-20 per 100,000 inhabitants.

"We commend the Brazilian government for recognizing nationwide health problems that exist, including Multiple Sclerosis and a multitude of other chronic medical conditions, and looking for solutions that can help alleviate those problems," said Medical Marijuana, Inc. CEO, Dr. Stuart Titus. "Brazil has embraced the therapeutic value of medical cannabinoids and is helping its people treat the symptoms of certain conditions with no known cure or limited treatment options."

"Research findings suggest that cannabis could slow the neurodegenerative process of MS and help patients manage the symptoms associated with their disease," added Dr. Titus. "For instance, one study showed cannabinoids demonstrated neuroprotective effects during an animal model of MS, reducing the damage to myelin caused from inflammation, while in another study MS patients saw significant improvements in muscle spasticity and reduced sleep disturbances after four weeks of cannabis treatments." 

"While our pharmaceutical development investment company, AXIM Biotech is researching a novel chewing gum delivery method involving cannabinoids to specifically treat pain and muscular spasticity in MS patients in European markets; a natural botanical CBD product is now available via HempMeds Brazil to potentially address some of the challenges that MS patients in Brazil are facing," Dr. Titus further expressed. "Although perhaps not as therapy specific as the pharmaceutically developed version, our natural botanical product may have benefit for improved quality of life for these medically challenged Brazilian patients."

In May 2015, HempMeds^® Brasil became the first company to offer legal medicinal cannabis products to Brazil after receiving import approval for those suffering from specific medical conditions. The Brazilian government now waives import taxes for RSHO™, subsidizes its cost and covers the product under the Country's health insurance.

About HempMeds® Brasil
HempMeds® Brasil currently has three cannabis products approved for importation into Brazil as a prescription medication for Epilepsy, Parkinson's and Chronic Pain. The company had the first-ever cannabis product allowed for import into Brazil and its products are currently subsidized by the Brazilian government, under their health care system, for all three medical indications listed above. HempMeds® Brasil is working on additional approvals for multiple indications.

About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.

To see Medical Marijuana, Inc.'s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.

FORWARD-LOOKING DISCLAIMER AND DISCLOSURES
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.

CONTACT:
Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829- 0070
[email protected]
www.cmwmedia.com

SOURCE Medical Marijuana, Inc.

Related Links

http://www.medicalmarijuanainc.com